TP Therapeutics raises $45m co-led by China's Lilly Asia Ventures

TP Therapeutics raises $45m co-led by China's Lilly Asia Ventures

California-based-TP Therapeutics, Inc, a clinical-stage biopharmaceutical company, has raised $45 million in Series C round of funding co-led by China’s Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One Ltd, the company said in a press release.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter